ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Walking inability in children during early treatment of acute lymphoblastic leukaemia: incidence and risk factors.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAcute lymphoblastic leukaemia (ALL) and its treatment cause side effects in paediatric patients which increase the risk of walking inability, limiting functional independence and quality of life. However, the incidence of walking inability, the time until onset and potential risk factors are unknown.
methodsWe retrospectively retrieved data in ALL patients (≤ 18 years). Walking inability was defined as the incompetence to walk independently from diagnosis until the end of early treatment. A Kaplan-Meier analysis was conducted to estimate the time until walking inability. To assess the effect of risk factors, we estimated a Cox regression model and performed a landmark analysis.
resultsIn total, 226 patients (age median, 5.5 years; interquartile range, 3.4-11.7) were included. Walking inability was experienced by 15.0% at diagnosis and 28.3% during induction/consolidation1. Age at diagnosis (hazard ratio (HR) 0.901; 95% confidence interval (CI) 0.847-0.959) was a risk factor during induction/consolidation1. The landmark analysis at end of induction identified age at diagnosis (HR 0.898; 95% CI 0.830-0.971), delta weight-to-height Z-score (HR 0.577; 95% CI 0.410-0.812) and duration of hospitalizations (HR 1.076; 95% CI 1.005-1.152) as risk factors during consolidation1.
conclusionFifteen percent experienced walking inability at diagnosis and 28.3% temporarily stopped walking during early treatment. This is concerning because walking inability leads to isolation and loss of independence. Patients with younger age, decreasing weight and longer hospitalizations during the first month of treatment were at highest risk. Informing patients and parents about the occurrence of walking inability and studies on physiotherapy and nutritional interventions are indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.